About
About Neurotech International Limited
Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute-onset neuropsychiatric syndrome, and Rett syndrome. It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary cannabis strains. The company has a collaboration with The University of Sydney. Neurotech International Limited was incorporated in 2016 and is based in Melbourne, Australia.
Visit company website
5 years, 5 months ago
Neurotech International Limited is currently in a long term uptrend where the price is trading 10.8% above its 200 day moving average.
From a valuation standpoint, the stock is 45.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 373.6.
Neurotech International Limited's total revenue sank by 22.7% to $31K since the same quarter in the previous year.
Its net income has dropped by 374.6% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 103.6% to $-445K since the same quarter in the previous year.
Based on the above factors, Neurotech International Limited gets an overall score of 1/5.